Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939246 · ClinicalTrials.gov registry record · NA
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
A NA study of Metastatic Carcinoma, sponsored by Baptist Health South Florida.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04939246: Completed NA study of Metastatic Carcinoma, sponsored by Baptist Health South Florida.
NCT04939246 is a NA study of Metastatic Carcinoma that has completed, run by Baptist Health South Florida. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04939246, a NA study of Metastatic Carcinoma, has completed, sponsored by Baptist Health South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
Primary Outcome
To be considered successful, SABR treatment must meet the following criteria: 1. Successful completion of treatment to each lesion within 3 days of intended treatment date 2. Successful completion of treatment to each lesion within 90 minutes from the patient entering the treatment room until treatment completion for at least 80% of treated lesions 3. Image guidance verification of treatment delivery within 5 mm of the planned delivery
Conditions Studied
Interventions
- RADIATION Stereotactic ablative body radiation therapy
Study Locations (2)
Florida
- Miami Cancer Institute at Baptist Health South Florida - Miami
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2024-07-17 |
| Phase | NA |
What the finished NCT04939246 record still lists
NCT04939246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Metastatic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic ablative body radiation therapy is the first listed.
NCT04939246 reports a single indexed study location in Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04939246 about?
NCT04939246 is a clinical study titled "Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction". This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation the...
What is the current status of trial NCT04939246?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-18. Estimated completion is 2024-07-17.
What conditions does trial NCT04939246 study?
This clinical trial studies the following conditions: Metastatic Carcinoma.
What interventions are being tested in trial NCT04939246?
The interventions under investigation include: Stereotactic ablative body radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04939246?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939246 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04939246's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI